Maximum quantity allowed is 999
Please select the quantity
CAS RN: 129-56-6 | Product Number: A2548
Anthra[1,9-cd]pyrazol-6(2H)-one
Purity: >95.0%(HPLC)
Synonyms:
- Dibenzo[cd,g]indazol-6(2H)-one
- SP 600125
Product Documents:
Size | Unit Price | Same Day | 2-3 Business Days |
---|---|---|---|
25MG |
NT$7,120
|
3 | 4 |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
Product Number | A2548 |
Purity / Analysis Method | >95.0%(HPLC) |
Molecular Formula / Molecular Weight | C__1__4H__8N__2O = 220.23 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Heat Sensitive |
Packaging and Container | 25MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 129-56-6 |
Reaxys Registry Number | 746890 |
PubChem Substance ID | 253659651 |
MDL Number | MFCD00022289 |
Specifications
Appearance | Light yellow to Yellow to Green powder to crystal |
Purity(HPLC) | min. 95.0 area% |
Properties (reference)
Melting Point | 282 °C |
GHS
Related Laws:
RTECS# | CB4585000 |
Transport Information:
H.S.code* | 2933.99-000 |
Application
LRRK2 Inhibitory Effect of SP600125
This product (SP600125) is an inhibitor of Jun N-terminal kinase (JNK), which is a stress-activated protein kinase that can be induced by inflammatory cytokines, bacterial endotoxin, osmotic shock, UV radiation, and hypoxia. In addition, there is a report that SP600125 inhibits LRRK2 (Leucine-rich repeat kinase 2) -G2019S, which is a promising therapeutic target for the treatment of Parkinson's disease, in the low micro-molar range. (The product is for research purpose only.)
References
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
- Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models (a review)
Application
Apoptosis
References
- PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells
- Nongenotropic, anti-apoptotic signaling of 1α,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes: MEDIATION BY Src, PHOSPHATIDYLINOSITOL 3-, AND JNK KINASES
Application
c-Jun N-Terminal Kinase (JNK) Inhibitor
References
- 1)SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
- 2)Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
- 3)A mammalian scaffold complex that selectively mediates MAP kinase activation
- 4)Scaffold proteins of MAP-kinase modules
- 5)Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1
PubMed Literature
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.